Evidence-based treatment for schizophrenia

被引:34
作者
Lehman, AF
Buchanan, RW
Dickerson, FB
Dixon, LB
Goldberg, R
Green-Paden, L
Kreyenbuhl, J
机构
[1] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA
[2] VA VISN 5 Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA
[3] Sheppard Pratt Hlth Syst, Catonsville, MD 21228 USA
[4] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA
关键词
D O I
10.1016/S0193-953X(03)00070-4
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In recent years, considerable progress has occurred in aggregating the results of treatment outcomes research for schizophrenia into summaries of evidence-based practices. This has permitted research to assess the quality of care afforded persons with this disorder. The findings have been that although the evidence base for effective treatment of schizophrenia is substantial, most people do not receive evidence-based treatment. Optimally effective evidence-based treatment consists of combined pharmacotherapy and psychosocial treatments. Future research must address the treatment of deficit symptoms and neurocognitive impairments, which account for much of the enduring disabling effects of this illness, and methods for ensuring that evidence-based treatments are disseminated and adopted into practice.
引用
收藏
页码:939 / +
页数:17
相关论文
共 86 条
[1]   Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia [J].
Addington, D ;
Addington, J ;
Patten, S ;
Remington, G ;
Moamai, J ;
Labelle, A ;
Beauclair, L .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) :20-25
[2]  
American Psychiatric Association, 1997, PRACT GUID TREATM PA
[3]  
[Anonymous], NEW PHARMACOTHERAPY
[4]  
ANTHONY WA, 1995, PSYCHIATR SERV, V46, P353
[5]   CLINICAL SERVICES RESEARCH [J].
ATTKISSON, C ;
COOK, J ;
KARNO, M ;
LEHMAN, A ;
MCGLASHAN, TH ;
MELTZER, HY ;
OCONNOR, M ;
RICHARDSON, D ;
ROSENBLATT, A ;
WELLS, K ;
WILLIAMS, J ;
HOHMANN, AA .
SCHIZOPHRENIA BULLETIN, 1992, 18 (04) :561-626
[6]   A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia [J].
Azorin, JM ;
Spiegel, R ;
Remington, G ;
Vanelle, JM ;
Péré, JJ ;
Giguere, M ;
Bourdeix, I .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) :1305-1313
[7]   Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder [J].
Bilder, RM ;
Goldman, RS ;
Volavka, J ;
Czobor, P ;
Hoptman, M ;
Sheitman, B ;
Lindenmayer, JP ;
Citrome, L ;
McEvoy, J ;
Kunz, M ;
Chakos, M ;
Cooper, TB ;
Horowitz, TL ;
Lieberman, JA .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (06) :1018-1028
[8]  
Blyler C.R., 2000, COGNITION SCHIZOPHRE, P241
[9]  
Bond GR, 1997, PSYCHIATR SERV, V48, P335
[10]  
Bond GR., 1999, J DISABIL POLICY STU, V10, P18, DOI DOI 10.1177/104420739901000104